Total Clarity Wealth Management Inc. Invests $386,000 in TransMedics Group, Inc. $TMDX

Key Points

• Total Clarity Wealth Management Inc. invested approximately $386,000 in TransMedics Group, acquiring 2,879 shares in the 2nd quarter.
• Institutional investors hold 99.67% of TransMedics Group's stock, indicating strong support from large financial entities.
• TransMedics Group's stock price target has been set at $127.18 by analysts, with a consensus rating of "Moderate Buy."

Total Clarity Wealth Management Inc. acquired a new position in shares of TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm acquired 2,879 shares of the company's stock, valued at approximately $386,000.

Other large investors also recently modified their holdings of the company. OneDigital Investment Advisors LLC grew its position in shares of TransMedics Group by 52.6% during the 1st quarter. OneDigital Investment Advisors LLC now owns 5,989 shares of the company's stock worth $403,000 after buying an additional 2,065 shares during the period. Principal Financial Group Inc. grew its position in shares of TransMedics Group by 2.8% during the 1st quarter. Principal Financial Group Inc. now owns 198,427 shares of the company's stock worth $13,350,000 after buying an additional 5,480 shares during the period. Vontobel Holding Ltd. acquired a new stake in shares of TransMedics Group during the 1st quarter worth approximately $291,000. New York State Teachers Retirement System grew its position in shares of TransMedics Group by 183.2% during the 1st quarter. New York State Teachers Retirement System now owns 21,949 shares of the company's stock worth $1,477,000 after buying an additional 14,200 shares during the period. Finally, Peregrine Capital Management LLC grew its stake in TransMedics Group by 3.4% in the first quarter. Peregrine Capital Management LLC now owns 68,390 shares of the company's stock valued at $4,601,000 after acquiring an additional 2,250 shares during the period. Institutional investors and hedge funds own 99.67% of the company's stock.

Analysts Set New Price Targets

A number of equities research analysts have commented on the company. Wall Street Zen cut TransMedics Group from a "buy" rating to a "hold" rating in a research note on Saturday, August 30th. Morgan Stanley raised their price objective on TransMedics Group from $115.00 to $123.00 and gave the company an "equal weight" rating in a research note on Friday, August 1st. Weiss Ratings reissued a "hold (c)" rating on shares of TransMedics Group in a research note on Wednesday, October 8th. Oppenheimer raised their price objective on TransMedics Group from $130.00 to $150.00 and gave the company an "outperform" rating in a research note on Tuesday, June 17th. Finally, Zacks Research cut TransMedics Group from a "strong-buy" rating to a "hold" rating in a research note on Monday, October 6th. Seven research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. According to data from MarketBeat, TransMedics Group currently has a consensus rating of "Moderate Buy" and an average price target of $127.18.

TransMedics Group Stock Up 4.1%

TMDX stock opened at $111.71 on Tuesday. The stock's 50 day moving average is $116.88 and its 200-day moving average is $112.70. The firm has a market capitalization of $3.81 billion, a PE ratio of 57.88 and a beta of 2.08. TransMedics Group, Inc. has a twelve month low of $55.00 and a twelve month high of $145.50. The company has a quick ratio of 9.17, a current ratio of 9.86 and a debt-to-equity ratio of 1.61.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last issued its quarterly earnings results on Wednesday, July 30th. The company reported $0.92 EPS for the quarter, topping analysts' consensus estimates of $0.48 by $0.44. The business had revenue of $157.37 million for the quarter, compared to analyst estimates of $146.64 million. TransMedics Group had a return on equity of 28.02% and a net margin of 13.49%.TransMedics Group's quarterly revenue was up 37.7% compared to the same quarter last year. During the same period last year, the company posted $0.35 earnings per share. TransMedics Group has set its FY 2025 guidance at EPS. Sell-side analysts expect that TransMedics Group, Inc. will post 1 EPS for the current fiscal year.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.

Want to see what other hedge funds are holding TMDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for TransMedics Group, Inc. (NASDAQ:TMDX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.